BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schlabe S, Rockstroh JK. Advances in the treatment of HIV/HCV coinfection in adults. Expert Opinion on Pharmacotherapy 2017;19:49-64. [DOI: 10.1080/14656566.2017.1419185] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
Number Citing Articles
1 Chen L, Du L, Kang S, Ma F, Li C, He M, Bai L, Tang H. Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China. Sci Rep 2021;11:11301. [PMID: 34050222 DOI: 10.1038/s41598-021-90706-5] [Reference Citation Analysis]
2 Onorato L, Pisaturo M, Starace M, Minichini C, Di Fraia A, Astorri R, Coppola N. Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review. Viruses 2021;13:432. [PMID: 33800289 DOI: 10.3390/v13030432] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Dinesh DC, Tamilarasan S, Rajaram K, Bouřa E. Antiviral Drug Targets of Single-Stranded RNA Viruses Causing Chronic Human Diseases. Curr Drug Targets 2020;21:105-24. [PMID: 31538891 DOI: 10.2174/1389450119666190920153247] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
4 Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019;394:1451-1466. [PMID: 31 DOI: 10.1016/s0140-6736(19)32320-7] [Cited by in Crossref: 108] [Cited by in F6Publishing: 56] [Article Influence: 2.3] [Reference Citation Analysis]
5 Shitole SG, Lazar JM, Hanna DB, Kim RS, Anastos K, Garcia MJ, Tien PC, Lima JAC, Kaplan RC, Kizer JR. HIV, hepatitis C virus and risk of new-onset left ventricular dysfunction in women. AIDS 2021;35:1647-55. [PMID: 33859109 DOI: 10.1097/QAD.0000000000002920] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Stanciu C, Muzica CM, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Huiban L, Chiriac S, Cuciureanu T, Trifan A. An update on direct antiviral agents for the treatment of hepatitis C. Expert Opin Pharmacother 2021;22:1729-41. [PMID: 33896315 DOI: 10.1080/14656566.2021.1921737] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Mocroft A, Lundgren JD, Rockstroh JK, Aho I, Wandeler G, Nielsen L, Edwards S, Viard JP, Lacombe K, Fätkenheuer G, Guaraldi G, Laguno M, Llibre J, Elinav H, Flamholc L, Gisinger M, Paduta D, Khromova I, Jilich D, Rozplochowski B, Oprea C, Peters L; EuroSIDA study . Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons. Open Forum Infect Dis 2020;7:ofaa470. [PMID: 33409325 DOI: 10.1093/ofid/ofaa470] [Reference Citation Analysis]
8 Zhu S, Liu B, Xu Y, Zhang L, Xia Z, Liu J, Zhou X, Fu Y, Allain J, Li C, Li T. Two New Purification Methods of Hepatitis C Virus Particles from Serum-Free Culture System. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.115727] [Reference Citation Analysis]
9 Mocroft A, Ryom L, Oprea C, Li Q, Rauch A, Boesecke C, Uzdaviniene V, Sedlacek D, Llibre JM, Lacombe K, Nielsen LN, Florence E, Aho I, Chkhartishvili N, Szlavik J, Dragovic G, Leen C, Sambatakou H, Staub T, Laguno M, Elinav H, Tomažič J, Peters L; EuroSIDA study group. Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons. AIDS 2020;34:1485-95. [PMID: 32675562 DOI: 10.1097/QAD.0000000000002570] [Reference Citation Analysis]
10 Mari PC, Gulati R, Fragassi P. Adolescent Hepatitis C: Prevalence, Impact, and Management Challenges. Adolesc Health Med Ther 2021;12:45-53. [PMID: 33994820 DOI: 10.2147/AHMT.S263864] [Reference Citation Analysis]
11 Londoño MC, Riveiro-Barciela M, Ahumada A, Muñoz-Gómez R, Roget M, Devesa-Medina MJ, Serra MÁ, Navascués CA, Baliellas C, Aldamiz-Echevarría T, Gutiérrez ML, Polo-Lorduy B, Carmona I, Benlloch S, Bonet L, García-Samaniego J, Jiménez-Pérez M, Morán-Sánchez S, Castro Á, Delgado M, Gea-Rodríguez F, Martín-Granizo I, Montes ML, Morano L, Castaño MA, de Los Santos I, Laguno M, Losa JE, Montero-Alonso M, Rivero A, de Álvaro C, Manzanares A, Mallolas J, Barril G, González-Parra E, García-Buey L. Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study. PLoS One 2019;14:e0221567. [PMID: 31550267 DOI: 10.1371/journal.pone.0221567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
12 Sarmento-Castro R, Méndez J, Horta A, Gonçalves C, Vasconcelos O, Seabra J, Abreu M, Gonçalves MJ, Santos MJ, Tavares AP. Hepatitis C treatment outcome in former or current intravenous drug users coinfected with HIV, with or without directly observed therapy. Infect Dis (Lond) 2021;53:9-18. [PMID: 32820689 DOI: 10.1080/23744235.2020.1806352] [Reference Citation Analysis]
13 Lions C, Laroche H, Zaegel-Faucher O, Ressiot E, Bregigeon S, Geneau de Lamarliere P, Solas C, Tamalet C, Pieve MA, Ritleng AS, Debreux C, Ivanova A, Obry-Roguet V, Carrieri P, Poizot-Martin I. Hepatitis C virus-microelimination program and patient trajectories after hepatitis C virus cure in an outpatient HIV clinical unit. Eur J Gastroenterol Hepatol 2020;32:1212-21. [PMID: 31851097 DOI: 10.1097/MEG.0000000000001640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Wagner R, Randolph JT, Patel SV, Nelson L, Matulenko MA, Keddy R, Pratt JK, Liu D, Krueger AC, Donner PL, Hutchinson DK, Flentge C, Betebenner D, Rockway T, Maring CJ, Ng TI, Krishnan P, Pilot-Matias T, Collins C, Panchal N, Reisch T, Dekhtyar T, Mondal R, Stolarik DF, Gao Y, Gao W, Beno DA, Kati WM. Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530). J Med Chem 2018;61:4052-66. [PMID: 29653491 DOI: 10.1021/acs.jmedchem.8b00082] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 6.5] [Reference Citation Analysis]
15 Aghemo A, Piroth L, Bhagani S. What do clinicians need to watch for with direct-acting antiviral therapy? J Int AIDS Soc 2018;21 Suppl 2:e25076. [PMID: 29633552 DOI: 10.1002/jia2.25076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
16 Zhang W, Aryan M, Qian S, Cabrera R, Liu X. A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis. Gastroenterology Res 2021;14:139-56. [PMID: 34267829 DOI: 10.14740/gr1405] [Reference Citation Analysis]
17 Carrasco I, Sainz T, Frick MA, Jiménez de Ory S, Fortuny C, Burgos J, Montero M, Gavilán C, Falcón MD, Couceiro JA, Bernardino JI, Bisbal O, Guerrero C, Aldámiz-Echevarría MT, Berenguer J, Navarro ML; the Pediatric National AIDS Research Network of Spain (CoRISpe) integrated in the Translational Research Network in Pediatric Infectious Diseases (RITIP). Response to direct-acting antivirals for hepatitis C treatment in vertically HIV/HCV co-infected patients. J Viral Hepat 2020;27:955-8. [PMID: 32347645 DOI: 10.1111/jvh.13308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Gupta E, Agarwal R, Rastogi A, Rani N, Jindal A. Naturally Occurring Resistance Associated Substitutions in Non-Cirrhotic, Treatment Naive HCV-HIV Co-Infected Patients Does Not Affect the Treatment Response for Anti-HCV Antiviral Therapy. Infect Drug Resist 2021;14:1381-7. [PMID: 33880042 DOI: 10.2147/IDR.S301032] [Reference Citation Analysis]
19 Heron JE, Bagnis CI, Gracey DM. Contemporary issues and new challenges in chronic kidney disease amongst people living with HIV. AIDS Res Ther 2020;17:11. [PMID: 32178687 DOI: 10.1186/s12981-020-00266-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
20 Huang Y, Sun M, Yang X, Ma A, Ma Y, Zhao A. Baicalin relieves inflammation stimulated by lipopolysaccharide via upregulating TUG1 in liver cells. J Physiol Biochem 2019;75:463-73. [PMID: 31396818 DOI: 10.1007/s13105-019-00698-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
21 Avramovic G, Reilly M, Cullen W, Macías J, McCombe G, McHugh T, Oprea C, Story A, Surey J, Sabin C, Bivegete S, Vickerman P, Walker J, Ward Z, Lambert JS. HEPCARE EUROPE- A case study of a service innovation project aiming at improving the elimination of HCV in vulnerable populations in four European cities. Int J Infect Dis 2020;101:374-9. [PMID: 32992012 DOI: 10.1016/j.ijid.2020.09.1445] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Wang B, Krüger L, Machnowska P, Eshetu A, Gunsenheimer-Bartmeyer B, Bremer V, Hauser A, Bannert N, Bock CT. Characterization of a hepatitis C virus genotype 1 divergent isolate from an HIV-1 coinfected individual in Germany assigned to a new subtype 1o. Virol J 2019;16:28. [PMID: 30832687 DOI: 10.1186/s12985-019-1135-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Pozza R, McCoy-Hill C, Hall K, Hefner A, Wilgers K, Tapelband J, Masroor M, Hassanein T. Eradicating hepatitis C virus: The APRN's role. Nurse Pract 2019;44:16-27. [PMID: 31567700 DOI: 10.1097/01.NPR.0000586008.23422.2c] [Reference Citation Analysis]
24 Shitole SG, Kuniholm MH, Hanna DB, Boucher T, Peng AY, Berardi C, Shah T, Bortnick AE, Christia P, Scheuer J, Kizer JR. Association of human immunodeficiency virus and hepatitis C virus infection with long-term outcomes post-ST segment elevation myocardial infarction in a disadvantaged urban community. Atherosclerosis 2020;311:60-6. [PMID: 32947199 DOI: 10.1016/j.atherosclerosis.2020.08.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Tran AN, Lim JK. Hepatitis C: How Good Are Real-Life Data and Do Generics Work. Gastroenterol Clin North Am 2020;49:279-99. [PMID: 32389363 DOI: 10.1016/j.gtc.2020.01.006] [Reference Citation Analysis]
26 Golchin A, Farahany TZ. Biological Products: Cellular Therapy and FDA Approved Products. Stem Cell Rev Rep. 2019;15:166-175. [PMID: 30623359 DOI: 10.1007/s12015-018-9866-1] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 25.0] [Reference Citation Analysis]
27 Liu CH, Sun HY, Hsieh SM, Liu WC, Sheng WH, Liu CJ, Su TH, Tseng TC, Chen PJ, Hung CC, Kao JH. Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy. J Viral Hepat 2021;28:887-96. [PMID: 33759290 DOI: 10.1111/jvh.13502] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Diaz NA, Ambrosioni J, Tuset M, Brunet M, Cofan F, Crespo G, Ruiz P, Redondo-Pachón D, Crespo M, Marín-Casino M, Moreno A, Miró JM; Hospital Clinic and Hospital del Mar SOT in HIV Investigators. Tacrolimus, Sirolimus and Everolimus Doses in HIV-Infected Solid-Organ Recipients, Requiring a Cobicistat-Based Antiretroviral Regimen: Report of Three Cases and Review. Infect Dis Ther 2021;10:1055-64. [PMID: 33830489 DOI: 10.1007/s40121-021-00430-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Ramezani A, Baesi K, Banifazl M, Mohraz M, Khorvash F, Yaran M, Tabarsi P, Dalirrooyfard AH, Motevalli F, Bavand A, Aghakhani A. Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in iranian population. Clin Res Hepatol Gastroenterol 2019;43:594-602. [PMID: 31080115 DOI: 10.1016/j.clinre.2019.01.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
30 Ellwanger JH, Kulmann-Leal B, Kaminski VL, Rodrigues AG, Bragatte MAS, Chies JAB. Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases. Virus Res 2020;286:198040. [PMID: 32479976 DOI: 10.1016/j.virusres.2020.198040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
31 Blumberg EA, Rogers CC; American Society of Transplantation Infectious Diseases Community of Practice. Solid organ transplantation in the HIV-infected patient: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33:e13499. [PMID: 30773688 DOI: 10.1111/ctr.13499] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
32 Solitano V, Plaz Torres MC, Pugliese N, Aghemo A. Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations? Viruses 2021;13:1048. [PMID: 34205966 DOI: 10.3390/v13061048] [Reference Citation Analysis]
33 Gonzales Zamora JA. Adverse Effects of Direct Acting Antivirals in HIV/HCV Coinfected Patients: A 4-Year Experience in Miami, Florida. Diseases 2018;6:E51. [PMID: 29921760 DOI: 10.3390/diseases6020051] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
34 Li L, Lin C, Liang LJ, Pham QL, Feng N, Nguyen AT. HCV infection status and care seeking among people living with HIV who use drugs in Vietnam. AIDS Care 2020;32:83-90. [PMID: 32297556 DOI: 10.1080/09540121.2020.1739209] [Reference Citation Analysis]